In addition, lower-cost treatment alternatives, such as metformin or DPP-4 inhibitors, are available for patients with type 2 diabetes.28 In contrast, the lack of effective alternative treatments for patients without type 2 diabetes may necessitate GLP-1 RA treatment regardless of cost. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.